These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 17361128

  • 1. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS, Brandt JT, Darstein C, Jakubowski JA, Salazar DE.
    Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
    [Abstract] [Full Text] [Related]

  • 2. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD, Li YG, Small DS, Ernest CS, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ.
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
    Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A.
    Eur Heart J; 2008 Jan; 29(1):21-30. PubMed ID: 18055486
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
    Payne CD, Li YG, Brandt JT, Jakubowski JA, Small DS, Farid NA, Salazar DE, Winters KJ.
    Platelets; 2008 Jun; 19(4):275-81. PubMed ID: 18569863
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
    Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Takahashi M, Kurihara A, Okazaki O, Farid NA, Ikeda T.
    Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Ernest CS, Small DS, Rohatagi S, Salazar DE, Wallentin L, Winters KJ, Wrishko RE.
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):593-618. PubMed ID: 19023649
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
    Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L.
    Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [Abstract] [Full Text] [Related]

  • 18. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, Lachno DR, Salazar D, Winters KJ.
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
    Small DS, Farid NA, Li YG, Ernest CS, Winters KJ, Salazar DE, Payne CD.
    J Clin Pharm Ther; 2009 Oct; 34(5):575-83. PubMed ID: 19744013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.